Risk stratification replaces “Stage 4” terminology, prioritizing prevention of arterial/venous thrombosis and bleeding events over tumor burden concepts. Diagnostic confirmation typically integrates ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...
Preliminary findings from 51 evaluable ET patients showed treatment with INCA033989 monotherapy demonstrated rapid and durable normalization of platelet counts. The Food and Drug Administration (FDA) ...
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to INCA033989, a first-in-class mutant calreticulin ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new research detailing the development and mechanism of action of INCA033989, an Incyte-discovered, investigational novel ...
Essential thrombocythemia (ET) is a rare condition affecting the bone marrow, resulting in an overproduction of platelets. It usually affects those over the age of 50, progresses slowly, and can be ...
To the authors’ knowledge, the study is the first to include a patient with essential thrombocythemia (ET) and MPL and Type 1 calreticulin gene mutations. Authors of a case study suggest screening for ...
Hosted on MSN
Understanding high platelet counts and your health
What it means: Thrombocytosis is a high platelet count, which can make blood too sticky and raise the risk of clot-related complications like stroke or heart attack. Two main types: Reactive ...
Appointed as Chief Development Officer, Alethio Therapeutics · GlobeNewswire Inc. Oxford, UK – 16th April 2026 - Alethio Therapeutics, a biopharmaceutical company developing novel treatments for ...
Please provide your email address to receive an email when new articles are posted on . In this video, Aaron T. Gerds, MD, MS, discussed treatment findings from a phase two study presented at ASH ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results